In particular, NGAL is emerging as an excellent biomarker in the urine and plasma for several processes such as early prediction of AKI, monitoring clinical trials in AKI, and for the prognosis of AKI in several common clinical scenarios [7]. Here, LCN2 is linked to acute kidney injury.